Why Cancer Drugs Fail FDA Approval: How Clinical Trial Teams Can Prevent Rejection Early
In oncology drug development, FDA rejection is often perceived as a late-stage failure, an FDA Complete Response Letter (CRL) that arrives after many years of pre-clinical development, years of intense clinical work, heavy capital investment, and deep, persistent patient needs....
